Genentech, Inc.
Clinical trials sponsored by Genentech, Inc., explained in plain language.
A biotechnology company developing and commercializing medicines for serious diseases, a wholly-owned subsidiary of Roche.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- SMA drug risdiplam under Long-Term watch: will it hold up? Results expected Oct 2026 (estimated)
- Can adding venetoclax let CLL patients pause therapy? Results expected Oct 2026 (estimated)
- Liver function may change how inavolisib works Results expected Nov 2026 (estimated)
- New eye drug shows promise for Diabetes-Related vision loss Results expected Nov 2026 (estimated)
- New combo tackles Hard-to-Treat myeloma Results expected Nov 2026 (estimated)
-
New hope for advanced breast cancer: experimental drug targets resistant tumors
Disease control Stopped earlyThis early-stage trial tests a new drug, GDC-0587, alone or with another drug (giredestrant), in people with advanced ER-positive, HER2-negative breast cancer whose cancer worsened after prior CDK4/6 inhibitor therapy. The study aims to find safe doses and check for side effects.…
Phase 1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for ulcerative colitis? drug trial shows promise
Disease control Stopped earlyThis study tested a drug called vixarelimab in 79 people with moderate to severe ulcerative colitis (UC) who had not responded well to other treatments. The goal was to see if the drug could help control the disease and reduce symptoms like diarrhea and bleeding. The study was st…
Phase 2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Experimental drug vixarelimab tested for two scarring lung diseases
Disease control Stopped earlyThis study tested the drug vixarelimab against a placebo in people with idiopathic pulmonary fibrosis (IPF) or systemic sclerosis-associated interstitial lung disease (SSc-ILD). The goal was to see if it could preserve lung function over 52 weeks. The trial was terminated early, …
Phase 2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New cancer drug trial cut short after early testing
Disease control Stopped earlyThis early-stage study tested a new drug called RO7759065, alone or with another drug (atezolizumab), in 12 people with advanced solid tumors that could not be cured. The main goals were to check safety and how the drug moves through the body. The study was stopped early, so resu…
Phase 1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Kidney shield? experimental drug aims to prevent Post-Surgery kidney damage
Prevention Stopped earlyThis phase 2 trial tested a drug called GDC-8264 to see if it could prevent acute kidney injury and major kidney problems in people having heart surgery. The study enrolled 67 participants at moderate to high risk. However, the trial was terminated early, so the full results are …
Phase 2 • Sponsor: Genentech, Inc. • Aim: Prevention
Last updated Jun 27, 2026 11:02 UTC